ABIVAX completes recruitment in its phase IIb/III pivotal study with ABX203, first-in-class therapeutic vaccine against chronic Hepatitis B
ABIVAX completes recruitment in its phase IIb/III pivotal study with ABX203, first-in-class therapeutic vaccine against chronic Hepatitis B
September 24, 2015
Download 465.4 KB
Paris, 24th September 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a leading clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced that it has completed enrollment of all 266 subjects into its pivotal Phase IIb/III clinical trial of ABX203, aimed at demonstrating the safety and efficacy of ABX203, a therapeutic vaccine candidate for the treatment of patients with chronic hepatitis B disease. This is a significant milestone for the company, which recently conducted an IPO on the regulated market of Euronext Paris and set a record among biotechnology companies in France in terms of the amount of funds raised.